The farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily and main nuclear bile acid receptor that regulates the expression of key target genes in bile acid, lipid, and glucose metabolism.1, 2, 3 The receptor is highly expressed in the liver and ileum and is involved not only in metabolic pathways but also in hepatic inflammation and fibrosis.4, 5 Accordingly, FXR agonists have been shown to reduce liver fibrosis, vascular remodeling, and sinusoidal dysfunction, as well as portal hypertension in experimental studies.6, 7. Here, NR1H4 is linked to portal hypertension.